By combining machine learning and T-cell engineering researchers were able to develop cell therapies that can selectively and effectively target and destroy solid tumours.
List view / Grid view
Filter the results
A research team has shown that T-cell responses specific to SARS-CoV-2 remain in the body after infection, providing immunity from mild re-infection.
Researchers demonstrate that the CARD8 protein plays a key role in regulating the inflammation that causes atherosclerosis and other inflammatory diseases.
Results of a recent study by researchers at the University of Bristol indicate neuropilin-1 is an important host factor for SARS-CoV-2 infection. The team suggests that blocking neuropilin-1 may be a valuable therapeutic intervention in the treatment of COVID-19. Nikki Withers spoke to one of the study’s lead investigators, Dr…
COVID-19 is known to infect the lungs; however, the dynamics of viral infection and replication are poorly understood. Alongside the Liverpool School of Tropical Medicine, Professor Lyle Armstrong and colleagues have been working to develop a human lung epithelium model of SARS-CoV-2 infection and replication. In this article, he describes…
Researchers from Massachusetts General Hospital have studied several thousand circulating proteins within the plasma proteome of symptomatic COVID-19 patients and acutely ill non-COVID-19 controls. Nikki Withers discussed their findings and implications of the study with one of the lead authors, Dr Mike Filbin.
This in-depth focus features articles on neuropilin-1, a potential new target for COVID-19 drug development, the creation of a lung model to enhance our understanding of SARS-CoV-2 infections and using proteomics to uncover the mechanisms behind COVID-19 symptom severity.
Researchers reveal how two genetic variations may contribute to COVID-19 disease severity and suggest the product of one, the CD209 antigen, may be a potential drug target.
Researchers have shown that 70 percent of Alzheimer’s patients have high levels of proteins associated with dysfunction in the endosomal trafficking system in their spinal fluid.
A model of a human lung cell has been used to understand how SARS-CoV-2 uses host cell processes to reproduce, revealing drug targets.
In this magazine find articles discussing antimicrobial resistance, exploring why inhibiting the interaction between SARS-CoV-2 and neuropilin-1 could help combat COVID-19, as well as how CRISPR can be used to enhance productivity in cell line development. Also in this issue, features on engineering new biologic drugs and precision medicine.
Researchers have analysed 750 samples from patients with SARS-CoV-2 to discover details about its transmission and mutational properties.
Researchers used integrative network biology analysis to identify the molecular mechanisms that may drive Alzheimer’s and identified a potential therapeutic intervention.
Scientists have shown how SARS-CoV-2 induces changes in the architecture of host cells to drive replication and made their data available to all.
A study in healthcare workers has shown that antibodies from COVID-19 infection protect individuals from reinfection for at least six months.